Cerebrospinal Fluid Concentrations of Idebenone in Friedreich Ataxia Patients

Abstract

We studied plasma and cerebrospinal fluid (CSF) concentrations of idebenone in five Friedreich ataxia patients on treatment with this antioxidant, and plasma and CSF ubiquinone-10 (Q₁₀) concentrations in 15 controls. CSF idebenone concentrations were below the detection limit in 3 Friedreich ataxia patients and no association could be demonstrated between plasma and CSF idebenone values. Q₁₀ CSF concentrations (median: 2.25 nmol/L) were approximately 300 times lower than those of plasma (median: 0.77 µmol/L). No correlation was observed between plasma and CSF Q₁₀ concentrations. A significantly positive correlation was observed between CSF total protein values (range 8.1 - 107.5 mg/dL; median: 29.5) and CSF Q₁₀ concentrations (Spearman test: r = 0.664; p = 0.01). Our findings suggest that less idebenone is distributed to the brain than to other tissues, although CSF does not appear to be an appropriate material for treatment monitoring of idebenone and other quinoid compounds.

Friedreich ataxia - idebenone - ubiquinone-10 - cerebrospinal fluid

References

• 1 Artuch R, Aracil A, Mas A, Colome C, Rissech M, Monros E. et al . Friedreich's ataxia: idebenone treatment in early stage patients.  Neuropediatrics. 2002;  33 190-193
• 2 Buyse G, Mertens L, Di Salvo G, Matthijs I, Weidemann F, Eyskens B. et al . Idebenone treatment in Friedreich's ataxia. Neurological, cardiac, and biochemical monitoring.  Neurology. 2003;  60 1679-1681
• 3 Colomé C, Artuch R, Vilaseca M A, Sierra C, Brandi N, Lambruschini N. et al . Lipophilic antioxidants in phenylketonuric patients.  Am J Clin Nutr. 2003;  77 185-188
• 4 Di Giovanni S, Mirabella M, Spinazzola A, Crociani P, Silvestri G, Broccolini A. et al . Coenzyme Q10 reverses pathological phenotype and reduces apoptosis in familial CoQ10 deficiency.  Neurology. 2001;  57 515-518
• 5 Ernster L, Dallner G. Biochemical, physiological and medical aspects of ubiquinone function.  Biochim Biophys Acta. 1995;  1271 195-204
• 6 Gabsi S, Gouider-Khouja N, Belal S, Fki M, Kefi M, Turki I. et al . Effect of vitamin E supplementation in patients with ataxia with vitamin E deficiency.  Eur J Neurol. 2001;  8 477-481
• 7 Gillis J C, Benefield P, McTavish D. Idebenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders.  Drugs Aging. 1994;  5 133-152
• 8 Grieb P, Ryba M S, Debicki G S, Gordon-Krajcer W, Januszeswski S, Chrapusta S J. Changes in oxidative stress in the rat brain during post-cardiac arrest reperfusion, and the effect of treatment with the free radical scavenger idebenone.  Resuscitation. 1998;  39 107-113
• 9 Mariotti C, Solari A, Torta D, Marano L, Fiorentini C, Di Donato S. Idebenone treatment in Friedreich patients: One-year-long randomized placebo-controlled trial.  Neurology. 2003;  60 1676-1679
• 10 Nagai Y, Yoshida K, Narumi S, Tanayama S, Nagaoka A. Brain distribution of idebenone and its effects on local cerebral glucose utilization in rats.  Arch Gerontol Geriatr. 1989;  8 257-272
• 11 Napolitano A, Salvetti S, Vista M, Lombardi V, Siciliano G, Giraldi C. Long-term treatment with idebenone and riboflavin in a patient with MELAS.  Neurol Sci. 2000;  21 981-982
• 12 Pappert E J, Tangney C C, Goetz C G, Ling Z D, Lipton J W, Stebbins G T. et al . Alpha-tocopherol in the ventricular cerbrospinal fluid of Parkinson's disease patients: dose-response study and correlations with plasma levels.  Neurology. 1996;  47 1037-1042
• 13 Pardridge W M. CNS drug design based on principles of blood-brain barrier transport.  J Neurochem. 1998;  70 1781-1792
• 14 Parnetti L. Clinical pharmacokinetics of drugs for Alzheimer's disease.  Clin Pharmacokinet. 1995;  29 110-129
• 15 Pisano P, Durand A, Autret E, Desnuelle C, Pinsard N, Serratrice G. et al . Plasma concentrations and pharmacokinetics of idebenone and its metabolites following single and repeated doses in young patients with mitochondrial encephalomyopathy.  Eur J Clin Pharmacol. 1996;  51 167-169
• 16 Ricciarelli R, Zingg J M, Azzi A. Vitamin E: protective role of a Janus molecule.  FASEB J. 2001;  15 2314-2325
• 17 Rustin P, von Kleist-Retzow J C, Chantrel-Groussard K, Sidi D, Munnich A, Rotig A. Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study.  Lancet. 1999;  354 477-479
• 18 Schippling S, Kontush A, Arlt S, Buhmann C, Sturenburg H J, Mann U. et al . Increased lipoprotein oxidation in Alzheimer's disease.  Free Rad Res. 2000;  28 351-360
• 19 Trouillas P, Takayanagi T, Hallett M, Currier R D, Subramony S H, Wessel K. et al . International Cooperative Ataxia rating scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology.  J Neurol Sci. 1997;  145 205-211
• 20 Vatassery G T, Fahn S, Kuskowski M A. Alpha tocopherol in CSF of subjects taking high-dose vitamin E in the DATATOP study. Parkinson Study Group.  Neurology. 1998;  50 1900-1902
• 21 Wakabayashi H, Nakajima M, Yamato S, Shimada K. Determination of idebenone in rat serum and brain by high-performance liquid chromatography using platinum catalyst reduction and electrochemical detection.  J Chromatogr. 1992;  573 154-157